enGene (NASDAQ:ENGN) Sees Unusually-High Trading Volume

Shares of enGene Holdings Inc. (NASDAQ:ENGN) saw strong trading volume on Friday . 99,116 shares changed hands during mid-day trading, an increase of 116% from the previous session’s volume of 45,947 shares.The stock last traded at $16.00 and had previously closed at $15.32.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. SVB Leerink initiated coverage on shares of enGene in a report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price target on the stock. Wells Fargo & Company initiated coverage on enGene in a report on Monday, April 22nd. They issued an “overweight” rating and a $30.00 price target on the stock. Leerink Partnrs restated an “outperform” rating on shares of enGene in a report on Tuesday, February 20th. Guggenheim assumed coverage on enGene in a research note on Monday, April 15th. They issued a “buy” rating and a $34.00 target price on the stock. Finally, UBS Group assumed coverage on shares of enGene in a research note on Thursday, March 28th. They set a “buy” rating and a $37.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $34.40.

enGene Stock Up 1.2 %

The stock has a fifty day simple moving average of $16.21.

Insider Transactions at enGene

In related news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the company’s stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $15.00, for a total value of $717,810.00. Following the completion of the sale, the insider now directly owns 3,036,153 shares of the company’s stock, valued at $45,542,295. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 13.70% of the company’s stock.

Hedge Funds Weigh In On enGene

Large investors have recently bought and sold shares of the business. Vivo Capital LLC purchased a new position in shares of enGene in the 4th quarter valued at $6,264,000. BVF Inc. IL purchased a new position in enGene in the fourth quarter valued at about $20,777,000. Omega Fund Management LLC bought a new position in enGene in the fourth quarter worth about $10,441,000. Finally, Fcpm Iii Services B.V. purchased a new stake in shares of enGene during the fourth quarter valued at about $80,097,000. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.